Agilent Technologies Inc.: Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Agilent Technologies (NYSE: A) said the EU approved its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma to identify patients whose tumors express PD-L1 and may be eligible for Merck’s KEYTRUDA (pembrolizumab). Agilent said it is the eighth CE-marked indication for this test.
How this was made
The 30-second read
Why it matters
The EU approval expands the companion diagnostic’s indicated use for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, and notes it is the eighth CE-marked companion diagnostic indication for this code in the EU.
Market read
A concrete EU regulatory milestone for a companion diagnostic tied to a major oncology drug can incrementally improve testing demand expectations.
What to watch
No data on incremental test volumes, pricing, or contract terms with Merck/MSD; adoption speed in EU labs could be slower than the headline implies.
Background
Agilent’s PD-L1 IHC 22C3 pharmDx (SK006) is used to assess PD-L1 expression to identify patients eligible for pembrolizumab (KEYTRUDA).
Ticker impact
Agilent received EU certification for PD-L1 IHC 22C3 pharmDx (SK006) as a companion diagnostic for KEYTRUDA in ovarian and related cancers.
Near-term upside bias for A on incremental diagnostics demand expectations; magnitude likely modest unless paired with guidance or volume disclosures.
The article is a regulatory/label expansion for a specific companion diagnostic indication, which can drive incremental testing volumes, but it provides no financial figures or sales guidance.
Market effects
Supports continued growth narrative for companion diagnostics and PD-1/PD-L1 testing in oncology across EU markets.
Improves access in the EU for PD-L1 testing tied to KEYTRUDA eligibility in ovarian, fallopian tube, and primary peritoneal carcinoma.
Reinforces the global PD-L1 IHC 22C3 pharmDx platform’s expanding indication footprint, potentially aiding future label expansions elsewhere.
Counterpoint
CE-mark indication expansions may not translate into immediate revenue upside if reimbursement, lab adoption, or KEYTRUDA patient volumes are the binding constraints.
Key entities
- companyAgilent Technologies
Receives EU certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for KEYTRUDA.
- drugKEYTRUDA (pembrolizumab)
Anti-PD-1 therapy whose eligibility is supported by the PD-L1 IHC 22C3 pharmDx test.
- companyMerck (MSD outside US/Canada)
Partnered in developing the companion diagnostic and is the manufacturer of KEYTRUDA.
